By Lung Cancer Europe
Published 13 November 2026 · Last updated 13 November 2026
On 12 November 2026, the European Parliament adopted its report on implementing Europe's Beating Cancer Plan by 447 votes to 66, with 91 abstentions, rejecting every amendment that would have weakened its prevention measures. The 2040 Tobacco-Free Generation goal, plain packaging, higher tobacco taxes and alcohol labelling all survived intact. Separately, and on almost the same day, the European Commission's own plan to revise EU tobacco law hit a procedural wall that could delay it into 2027. This piece sets out what MEPs voted for, what is happening on the Commission side, and what it means for tobacco control and lung cancer prevention across Europe.
Key points
MEPs rejected all 20 tabled amendments to the Beating Cancer Plan implementation report, including one backed by 38 EPP members that would have softened the call for tobacco reform.
The adopted text calls for an urgent revision of EU tobacco legislation to cover e-cigarettes, heated tobacco products and nicotine pouches, alongside plain packaging, advertising limits and higher excise duties.
The Commission's own tobacco law revision is delayed. Its Regulatory Scrutiny Board gave a second negative opinion on the impact assessment behind the planned revision, pushing the proposal's expected publication from the end of 2026 into 2027.
Not every result went Lung Cancer Europe's way. Two amendments the organisation supported, on school meals and a Cancer Survivor Smart Card, also fell, as groups appear to have voted against all amendments to protect the committee's original text.
In this article
What did the European Parliament vote for?
Is the 2040 Tobacco-Free Generation goal still in place?
Why has the Tobacco Products Directive revision been delayed?
What does this mean for lung cancer prevention?
What happens next?
FAQs
What did the European Parliament vote for?
Parliament's plenary debate on the report, known in Brussels as the BECA report (Europe's Beating Cancer Plan), took place on 11 November, with the vote the following day. Rapporteur Vlad Vasile-Voiculescu (Renew) opened the debate by naming tobacco as the leading risk factor in cancer, responsible for one in five cancer deaths, nine in ten lung cancers and around 20 other cancer types. He pointed to a 22% rise in e-cigarette use among young people over five years, including children under 14, as a reason the EU's tobacco rules need updating without delay.
The report was not without disagreement. Pietro Fiocchi (ECR) called for more evidence comparing traditional smoking with "alternative" nicotine products, and several EPP speakers, including Jessica Polfjärd, András Kulja and Sunčana Glavak, focused less on tobacco specifically and more on unequal access to cancer care across member states and the need to measure success in patient outcomes rather than funded projects. Alessandra Moretti (S&D) and Tilly Metz (Greens/EFA) argued strongly against any weakening of the prevention measures, with Metz warning that cancer is on track to become the EU's leading cause of death by 2040, a 26% increase, and that prevention should not be overshadowed by economic interests.
When it came to the vote, all 20 tabled amendments were rejected, so the text Parliament adopted is the one its Public Health Committee had already agreed, with its prevention language intact. A closer look at the numbers adds some nuance. Amendment 12, tabled by 38 EPP MEPs to soften the call for tobacco reform from "without further delay" to "in due time", still lost by close to 190 votes, suggesting most EPP members voted against it or abstained despite the public divisions aired in the debate. The amendments targeting tobacco measures specifically, covering plain packaging, point-of-sale displays, health warnings, excise duties and smoke-free environments, lost by even wider margins, at least 420 votes against in each case.
Not every outcome favoured prevention advocates equally. Two amendments Lung Cancer Europe had supported, one on access to school meals and one creating a voluntary Cancer Survivor Smart Card, also fell. This most likely reflects political groups voting against all amendments as a bloc to protect the committee's text rather than opposition to those specific ideas, but it is a reminder that this was not a uniform win on every point.
Is the 2040 Tobacco-Free Generation goal still in place?
Yes. The 2040 Tobacco-Free Generation goal, first set out in Parliament's 2022 cancer resolution and aiming for under 5% tobacco use across the EU by that date, was directly targeted by one of the 20 tabled amendments. Amendment 14 would have replaced the explicit 2040 goal and the call for a prompt revision of EU tobacco legislation with weaker language. Because Parliament rejected every tabled amendment on 12 November, Amendment 14 failed along with the rest, and the 2040 goal remained in the adopted text, alongside plain packaging, higher tobacco taxes and alcohol labelling requirements. These were the specific provisions Lung Cancer Europe had asked MEPs to protect in its statement ahead of the vote, and all of them survived the amendment process untouched.
Why has the Tobacco Products Directive revision been delayed?
Parliament's vote is a political signal, not a change in law. The report is a non-binding, own-initiative resolution, so it sets out Parliament's position without obliging the Commission to act on any particular timeline. The actual mechanism for updating EU tobacco rules is a revision of the Tobacco Products Directive (TPD) and the Tobacco Advertising Directive, which is the Commission's responsibility to propose.
That process ran into trouble almost immediately. On 9 November, three days before Parliament's vote, the Commission's Regulatory Scrutiny Board, the internal body that reviews the quality of its impact assessments, issued a second negative opinion on the assessment underpinning the planned TPD revision. Reported concerns included weak analysis of the proportionality of the proposed measures, an absence of specific analysis of their tax implications, inadequate assessment of socioeconomic consequences, and scepticism about the evidence for the "gateway effect", the idea that e-cigarette use leads to conventional smoking. Some of the criticism reportedly also questioned the legal basis for EU-level restrictions justified on public health grounds.
A negative opinion means the Commission's Directorate-General for Health and Food Safety must revise and resubmit the impact assessment before the proposal can proceed. Health Commissioner Olivér Várhelyi had wanted the College of Commissioners to approve the proposal at its final meeting of the year on 15 December. That now looks unlikely, with 2027 the more realistic timeline. A Commission spokesperson said the proposal is still being advanced but gave no revised date.
The same week brought a related setback on tobacco taxation. On 9 November, EU finance ministers failed to reach unanimous agreement on revisions to the Tobacco Taxation Directive after Malta withheld support, underlining that tobacco reform is facing resistance on more than one front within the EU's institutions.
What does this mean for lung cancer prevention?
Tobacco causes around nine in ten lung cancers, so the gap between political support and binding law matters for how quickly prevention actually improves. Parliament's vote shows sustained, cross-party backing for stronger tobacco control, including rules that would, for the first time, bring e-cigarettes, heated tobacco products and nicotine pouches under the same kind of regulation as cigarettes. That is a meaningful signal, and one Lung Cancer Europe had specifically asked MEPs to protect.
But a political statement from Parliament does not itself change what is sold, advertised or taxed anywhere in the EU. That depends on the Commission successfully revising the TPD and TAD, and on member states then transposing whatever is agreed into national law. With the impact assessment now sent back for rework twice, and the Commission's own target date slipping from this December into next year, the practical update to Europe's tobacco rules, the one that would reach shop shelves, advertising and new nicotine products, is further away than the strength of Thursday's vote might suggest.
Lung Cancer Europe's position statement on Europe's Beating Cancer Plan sets out the full case for why tobacco control, screening and equal access to treatment need to move together, and our news coverage from 10 November has more detail on what the organisation asked MEPs to protect ahead of the vote.
What happens next?
The Commission must rework its impact assessment and resubmit it to the Regulatory Scrutiny Board before any revised Tobacco Products Directive or Tobacco Advertising Directive can be proposed. No new date has been confirmed, though 2027 is the figure now being reported. Once a proposal is eventually tabled, it would still need to go through the full EU legislative process, negotiation between Parliament and the Council, before becoming law, so any practical change to tobacco rules remains some way off.
Parliament's resolution, meanwhile, keeps the pressure on. Non-binding reports like this one are one of the tools national and European advocacy organisations use to hold the Commission and member states to the commitments they have already made. Lung Cancer Europe will continue to follow the Commission's revised tobacco proposal as it develops, and to press for the timely EU-wide protections this vote reaffirmed.
Member organisations who want to understand how this fits into the wider Beating Cancer Plan picture can read our full position statement, linked below.
FAQs
What is Europe's Beating Cancer Plan?
It is the European Commission's strategy, launched in 2021, for tackling cancer across the EU through prevention, early detection, treatment and support for people living with and beyond cancer. Parliament's 12 November report assessed how well that plan is being implemented and called for stronger action in several areas, including tobacco control.
What is the Tobacco Products Directive?
It is the main EU law setting rules for how tobacco and related products are manufactured, presented and sold, covering areas such as packaging, ingredients and advertising. The Commission has been preparing a revision to bring newer products like e-cigarettes, heated tobacco and nicotine pouches under similar rules, but that revision is now delayed.
Is the 12 November vote legally binding?
No. It is an own-initiative report, which means it sets out Parliament's political position and priorities but does not create new law or bind the Commission to a particular timeline.
Why does tobacco regulation matter specifically for lung cancer?
Tobacco use causes around nine in ten lung cancers, more than any other single risk factor. Measures such as plain packaging, advertising restrictions and higher taxes are among the most evidence-backed tools for reducing smoking rates, and therefore lung cancer incidence, over time.
When will the EU's new tobacco rules actually take effect?
Not soon. The Commission's proposal for revised rules needs to pass a reworked impact assessment, likely pushing publication into 2027, and would then still need to go through negotiation between Parliament and the Council before becoming law.
Final thoughts
Parliament's vote on 12 November was a clear, cross-party reaffirmation that tobacco control remains central to Europe's fight against cancer, with the 2040 Tobacco-Free Generation goal and other key prevention measures emerging from the amendment process untouched. But the same week exposed how far that political will still has to travel before it becomes enforceable law, with the Commission's own tobacco directive revision now facing a second rejected impact assessment and a likely delay into 2027. Lung Cancer Europe will keep tracking both strands, the political and the legislative, as they develop.
Read our position statement on Europe's Beating Cancer Plan for the organisation's full set of policy asks, or see our earlier coverage of the vote itself for what Lung Cancer Europe asked MEPs to protect before they voted.
About Lung Cancer Europe
Lung Cancer Europe is a pan-European advocacy organisation working for equal access to high-quality lung cancer care across Europe. Our members are national lung cancer advocacy organisations, and we bring their evidence and experience to European policymakers. Through our annual Lung Cancer Europe Reports, our Charter and the Get Checked! campaign, we work to improve diagnosis, treatment and support for everyone affected by lung cancer.
References
European Parliament. Report on the implementation of Europe's Beating Cancer Plan (rapporteur Vlad Vasile-Voiculescu), adopted 12 November 2026. Plenary vote record.
Eunews. "The European Parliament approves the Cancer Plan but the European tobacco reform has stalled at the technical review stage," 12 November 2026. Article
EU Reporter / London Globe. "Cancer plan vote exposes EPP divisions as Commission tobacco overhaul faces reported setback," 12 November 2026. Article
Tobacco Reporter. "EU Commission Watchdog Rejects Tobacco Impact Assessment," 13 November 2026. Article
Table.Briefings. "Tobacco Products Directive: Proposal rejected by the scrutiny board," 12 November 2026. Article
Agence Europe. "European Parliament calls for more resources for prevention in cancer plan." Article
Smoke Free Partnership. "Smoke Free Partnership welcomes European Parliament call to revise EU tobacco legislation without further delay," 12 November 2026. Press release
Lung Cancer Europe. "MEPs Urged to Protect Tobacco Prevention in Cancer Plan," 10 November 2026. Article